Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

NCT03425461 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped funding

Conditions

Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL: Anti-SEMA4D Monoclonal Antibody VX15/2503
BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Pharmacological Study

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]